|
| Author/Publication year | Country | Cohort | Number | Gender(M/F) | Age (years old) | ECOG | Primary tumor |
|
| Kang MJ, et al. [14] | Korea. | GemCis | 49 | 31/18 | 59(32-77) | 0-1:42(86%) 2:7(14%) | ICC:20(41%)ECC:29(59%) |
| S1Cis | 47 | 31/16 | 60(36-77) | 0-1:43(91%) 2:4(9%) | ICC:18(38%)ECC:29(62%) |
|
| Li H, et al. [22] | China. | Gem | 25 | 16/9 | 55.1±8.5 | NR | NR |
| S1 | 25 | 19/6 | 56.8±7.9 | NR | NR |
| GemS1 | 25 | 19/6 | 57.0±7.2 | NR | NR |
|
| Morizane C, et al. [15] | Japan. | GemS1 | 51 | 27/24 | 66.0(39-78) | 0:39(76.5%) 1:12(23.5%) | ICC:20(39.2%)CC:9(17.6%)GC:19(37.3%)AV:3(5.9%) |
| S1 | 50 | 28/22 | 62.5(49-79) | 0:37(74.0%) 1:13(26.0%) | ICC:20(39.2%)ECC:9(17.6%)GC:19(37.3%)AV:3(5.9%) |
|
| Santoro A, et al. [9] | Italy. | Vandetanib | 59 | 25/34 | 62.4±10.1 | 0:38(64.4%) 1:20(33.9%) 2:1(1.7%) | ICC:27(45.8%)ECC:16(27.1%)GC:11(18.6%)AV:5(8.5%) |
| Gem+Vandetanib | 58 | 31/27 | 64.4±9.5 | 0:36(61.0%) 1:20(33.9%) 2:3(5.1%) | ICC:31(53.4%)ECC:10(17.3%)GB:13(22.4%)AV:4(6.9%) |
| Gem | 56 | 25/31 | 64.0±8.8 | 0:34(61.8%) 1:20(36.4%) 2:1(1.8%) | ICC:29(52.7%)ECC:13(22.4%)GC:7(12.7%)AV:6(10.9%) |
|
| Sharma A, et al. [6] | India. | BSC | 27 | 6/21 | Median:51 | ≤2:27(100%) | GC:27(100%) |
| FUFA | 28 | 5/23 | Median:47 | ≤2:28(100%) | GC:28(100%) |
| GemOxa | 26 | 5/21 | Median:49 | ≤2:26(100%) | GC:26(100%) |
|
| Lee J, et al. [16] | Korea. | GemOxa | 133 | 79/54 | 61(55-68) | 0:20(15%) 1:100(75%) 2:13(10%) | CC:84(63%)GC:47(35%)AV:2(2%) |
| GemOxa+Erlotinib | 135 | 91/44 | 59(54-66) | 0:26(19%) 1:104(77%) 2:5(4%) | CC:96(71%)GC:35(26%)AV:4(3%) |
|
| Malka D, et al. [10] | France. Germany. | GemOxa+Cetuximab | 76 | 43/33 | 61(35-75) | 0:35(46%)1:36(47%)2:0(0%)Unspecified:5(7%) | CC:62(82%)GC:11(14%)AV:1(1%)Multifocal:1(1%)Unspecified:1(1%) |
| GemOxa | 74 | 42/32 | 62(39-75) | 0:27(36%) 1:42(57%) 2:1(1%) Unspecified:4(5%) | CC:61(82%)GC:11(15%)AV:0(0%)Multifocal:1(1%)Unspecified:1(1%) |
|
| Valle JW, et al. [11] | UK. | GemCis+Cediranib | 62 | 34/28 | 68.0(60.4-73.0) | 0:27(44%) 1:35(56%) | ICC:14(23%)ECC:24(39%)GC:20(32%)AV:4(6%) |
| GemCis | 62 | 28/34 | 64.5(59.7-73.1) | 0:28(45%) 1:34(55%) | ICC:15(24%)ECC:24(39%)GC:19(31%)AV:4(6%) |
|
| Phelip JM, et al. [17] | France. | FOLFIRINOX | 94 | 57/37 | 65(58-70) | 0:45(47.9%) 1:48(52.1%) | ICC:60(63.8%)ECC:18(19.1%)GC:16(17.1%) |
| GemCis | 96 | 47/49 | 63(55-67) | 0:46(47.9%) 1:50(52.1%) | ICC:59(61.5%)ECC:20(20.8%)GC:17(17.7%) |
|
| Valle JW, et al. [18] | UK. | GemCis+Ramucirumab | 106 | 46/60 | 64(58-71) | 0:45(43%) 1:58(55%) Missing:3(2%) | ICC:56(53%)GC:24(23%)ECC:18(17%)AV:8(8%) |
| GemCis+Merestinib | 102 | 48/54 | 62(56-67) | 0:52(51%) 1:50(49%) Missing:0(0%) | ICC:60(59%)GC:22(22%)ECC:14(14%)AV:6(6%) |
| GemCis | 101 | 53/48 | 59(52-68) | 0:61(60%) 1:39(39%) Missing:1(1%) | ICC:55(55%)GC:26(26%)ECC:14(14%)AV:5(5%) |
|
| Morizane C, et al. [7, 26] | Japan. | GemCis | 175 | 99/76 | 67(41-78) | 0:130(74%) 1:45(26%) | GC:68(39%)ICC:50(29%)ECC:49(28%)AV:7(4%) |
| GemS1 | 179 | 97/82 | 67(27-79) | 0:124(69%) 1:55(31%) | GC:69(39%) ICC:44(25%) ECC:59(33%) AV:6(3%) |
|
| Kim ST, et al. [8] | Korea. | GemOxa | 114 | 70/44 | 64.0(35.0-83.0) | 0:25(22%) 1:86(75%) 2:3(2%) | CC:84(74%) GC:30(26%) |
| XELOX | 108 | 74/34 | 62.0(28.0-84.0) | 0:35(32%) 1:71(66%) 2:1(1%) | CC:77(71%)GC:31(29%) |
|
| Sasaki T, et al. [19] | Japan. | GemS1 | 30 | 16/14 | 68(47-83) | 0:18(60%) 1:11(37%) 2:1(3%) | GC:16(53%)ICC:8(27%)ECC:6(20%) |
| Gem | 32 | 20/12 | 75(55-86) | 0:18(56%) 1:12(38%) 2:2(6%) | GC:14(44%)ICC:8(25%)ECC:10(31%) |
|
| Valle J, et al. [4] | UK. | Gem | 206 | 98/108 | 63.2(23.4-84.8) | 0:64(31.1%) 1:117(56.8%)2:24(11.7%) | GC:76(36.9%)CC:119(57.8%)AV:11(5.3%) |
| GemCis | 204 | 96/108 | 63.9(32.8-81.9) | 0:66(32.4%) 1:111(54.4%)
2:27(13.2%) | GC:73(35.8%)CC:122(59.8%)AV:9(4.4%) |
|
| Oh DY, et al.2022 [12] | Multiple counties | GemCis+Durvalumab | 341 | 169/172 | 64(20-84) | 0:50.7% | NR |
| GemCis | 344 | 176/168 | 64(31-85) | 0:47.4% | NR |
|
| Sharma A, et al. [20] | India. | GemOxa | 119 | 43/76 | 48.1±9.92 | 0:7(5.9%)1:72(60.5%)2:40(33.6%) | GC:119(100%) |
| GemCis | 124 | 39/85 | 47.8±12.05 | 0:7(5.6%)1:64(51.6%)2:53(42.7%) | GC:124(100%) |
|
| Leone F, et al. [21] | Italy. | GemOxa+Panitumumab | 45 | 17/28 | 63.9(46.7-78.5) | 0-1:45(100%) | ICC: 21 (46.7%)ECC: 21 (26.7%)GC: 12 (26.6%) |
| GemOxa | 44 | 15/29 | 64.2(36.8-78.5) | 0-1:43(97.7%)2:1(2.3%) | ICC: 21 (47.7%)ECC: 7 (15.9%)GC: 16 (36.4%) |
|
